On the Process of Discovering Leads That Target the Heparin-Binding Site of Neutrophil Elastase in the Sputum of Cystic Fibrosis Patients

Authors:

Abstract
Cystic fibrosis (CF) is a disease of dysregulated salt and fluid homeostasis that results in massive accumulation of neutrophil elastase resulting in lung degradation and death. The current CF therapy relies on inhaled deoxyribonuclease and hypertonic saline, but does not address elastolytic degradation of the lung. We reasoned that allosteric agents targeting the heparin-binding site of neutrophil elastase would offer a therapeutic paradigm. Screening a library of 60 non-saccharide glycosaminoglycan mimetics (NSGMs) led to discovery of 23 hits against neutrophil elastase. To identify a lead NSGM that works in sync with the current CF relieving agents, we developed a rigorous protocol based on fundamental computational, biochemical, mechanistic, and adverse effects studies. The lead NSGM so identified neutralized neutrophil elastase present in the sputum of CF patients in the presence of deoxyribonuclease and high salt conditions. Our work presents the process for discovering potent, small, synthetic, allosteric, anti-CF agents, while also identifying a novel lead for further studies in animal models of CF.
Funding Information
  • National Heart, Lung, and Blood Institute (P01 HL107152, R01 HL090586, K12 HL141954, HL128639)
  • Cystic Fibrosis Foundation (Voynow1510)
  • Virginia Commonwealth Health Research Board

This publication has 49 references indexed in Scilit: